December 2022
Volume 63, Issue 13
Open Access
Retina  |   December 2022
Photoreceptor Function and Structure in Autosomal Dominant Vitelliform Macular Dystrophy Caused by BEST1 Mutations
Author Affiliations & Notes
  • Artur V. Cideciyan
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Samuel G. Jacobson
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Malgorzata Swider
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Alexander Sumaroka
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Rebecca Sheplock
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Arun K. Krishnan
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Alexandra V. Garafalo
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Karina E. Guziewicz
    Division of Experimental Retinal Therapies, Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Gustavo D. Aguirre
    Division of Experimental Retinal Therapies, Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • William A. Beltran
    Division of Experimental Retinal Therapies, Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Elise Heon
    Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, University of Toronto, Toronto, Canada
  • Correspondence: Artur V. Cideciyan, Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; [email protected]
Investigative Ophthalmology & Visual Science December 2022, Vol.63, 12. doi:https://doi.org/10.1167/iovs.63.13.12
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Artur V. Cideciyan, Samuel G. Jacobson, Malgorzata Swider, Alexander Sumaroka, Rebecca Sheplock, Arun K. Krishnan, Alexandra V. Garafalo, Karina E. Guziewicz, Gustavo D. Aguirre, William A. Beltran, Elise Heon; Photoreceptor Function and Structure in Autosomal Dominant Vitelliform Macular Dystrophy Caused by BEST1 Mutations. Invest. Ophthalmol. Vis. Sci. 2022;63(13):12. https://doi.org/10.1167/iovs.63.13.12.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study was to evaluate rod and cone function and outer retinal structure within macular lesions, and surrounding extralesional areas of patients with autosomal dominant Best vitelliform macular dystrophy caused by BEST1 mutations.

Methods: Seventeen patients from seven families were examined with dark- and light-adapted chromatic perimetry and optical coherence tomography. Subsets of patients had long-term follow-up (14–22 years, n = 6) and dark-adaptation kinetics measured (n = 5).

Results: Within central lesions with large serous retinal detachments, rod sensitivity was severely reduced but visual acuity and cone sensitivity were relatively retained. In surrounding extralesional areas, there was a mild but detectable widening of the subretinal space in some patients and some retinal areas. Available evidence was consistent with subretinal widening causing slower dark-adaptation kinetics. Over long-term follow-up, some eyes showed formation of de novo satellite lesions at retinal locations that years previously demonstrated subretinal widening. A subclinical abnormality consisting of a retina-wide mild thickening of the outer nuclear layer was evident in many patients and thickening increased in the subset of patients with long-term follow-up.

Conclusions: Outcome measures for future clinical trials should include evaluations of rod sensitivity within central lesions and quantitative measures of outer retinal structure in normal-appearing regions surrounding the lesions.

Best vitelliform macular dystrophy (BVMD) is an autosomal dominant macular disease with a distinct ophthalmoscopic appearance1 caused by monoallelic mutations in BEST1.2,3 Over the last decade, it has become clear that BVMD is the most prevalent member of a spectrum of dominant and recessive inherited retinal pigment epithelium (RPE) diseases collectively named bestrophinopathies caused by both monoallelic as well as biallelic mutations in BEST1.2,47 Patients with BVMD tend to show pathognomonic macular lesions centered on or near the fovea, and disease is thought to progress through stages descriptively named based on their ophthalmoscopic appearances such as vitelliform, pseudohypopyon, or vitelliruptive leading to an atrophic/cicatricial appearance.79 Common to the earlier stages of disease is a serous detachment of the retina from the RPE, which is consistent with the understanding that the molecular defect acts primarily at the interface of photoreceptor outer segments and the RPE apical processes10,11 despite Bestrophin-1 being localized to the basolateral plasma membrane of the RPE.12,13 Later stages of BVMD can demonstrate substantial loss of photoreceptors and RPE that is localized to the macular area surrounded by wide expanses of retina that appear to demonstrate normal structure and normal function except for an electrophysiological defect detected by electrooculography (EOG).8,14 Some patients with monoallelic BEST1 mutations develop one or more extra central lesions and this phenotype is called multifocal vitelliform dystrophy.7 
In patients, BVMD is currently not curable or treatable. In dogs with naturally occurring biallelic BEST1 mutations, gene augmentation therapy has shown promise in treating both central vitelliform lesions as well as peripheral subclinical abnormalities.11 Although gene therapy has not yet been tried in dogs heterozygous for BEST1 mutations, two independent investigations in patient cells have supported the hypothesis that at least a subset of monoallelic BVMD mutations may indeed be amenable to gene augmentation therapy.15,16 In addition, small molecules have been proposed as BVMD therapies.17 Such investigational interventions will likely target macular lesions in BVMD as well as surrounding clinically uninvolved retina. In order to plan for appropriate outcome measures, we evaluated rod- and cone-photoreceptor mediated function within macular lesions and investigated subcellular retinal structure of the clinically uninvolved extralesional areas and peripheral retina. 
Methods
Subjects
The study population consisted of 17 patients with BVMD (ages 6–59 at first visit) from 7 families. Patients were heterozygous for BEST1 gene mutations (see the Table). Results in a subset of 10 patients have been published approximately 20 years earlier.18 Seven of 17 patients (5 of the 10 published earlier18 and 2 additional patients, see the Table) were evaluated most recently 4 to 22 years (median = 18 years) after their initial visit. Procedures followed the Declaration of Helsinki, and the study was approved by the Institutional Review Board (IRB) of the University of Pennsylvania. Informed consent, assent, and parental permission were obtained, and the work was Health Insurance Portability and Accountability Act (HIPAA)-compliant. 
Table.
 
Demographics and Genetics of Patients with BEST1-BVMD
Table.
 
Demographics and Genetics of Patients with BEST1-BVMD
Measures of Rod and Cone Function
Static threshold perimetry was performed in fully dilated eyes under dark- and light-adapted conditions using the modified Humphrey field analyzer (Carl Zeiss Meditec, Dublin, CA, USA), as previously described.19,20 Dark-adapted test conditions included monochromatic blue (B; 500 nm) and red (R; 650 nm) stimuli (1.7 degrees diameter Goldmann V size, 200 ms duration) used to determine photoreceptor mediation. For loci demonstrating rod mediation with the B stimulus, rod sensitivity loss (RSL) was obtained by subtraction of the B sensitivity from mean normal value at each locus. Light-adapted testing was performed with orange (O; 600 nm) stimuli presented on a 10 cd.m−2 white background and cone sensitivity loss (CSL) was obtained by subtraction of O sensitivity from mean normal value at each locus. Fixation during visual field testing was monitored via the infrared video imaging. Two profile tests extending 60 degrees along the horizontal and vertical meridia centered at fixation (29 loci separated by intervals of 2 degrees) were recorded. In addition, foveal sensitivity was measured at the center of four fixation lights forming a diamond. 
Retinal Imaging
A confocal scanning laser ophthalmoscope (HRA2 or Spectralis HRA; Heidelberg Engineering, Heidelberg, Germany) was used to obtain near-infrared excited reduced-illuminance autofluorescence imaging (NIR-RAFI).21 Wide field image montage was assembled by manually specifying corresponding retinal landmark pairs in overlapping segments using custom-written software (MATLAB version 6.5). 
Optical coherence tomography (OCT) was used to quantify retinal laminar architecture according to previously published methodology.18,2226 In brief, the main OCT data originated from 22 eyes of 11 patients recorded with a spectral-domain OCT (SD-OCT) instrument (RTVue-100; Optovue, Fremont, CA, USA). Data included overlapping line scans along the horizontal and vertical meridia extending to 30 degrees eccentricity, and overlapping raster scans with a coverage extending to 30 to 40 degrees eccentricity. In a subset of six eyes of six patients, long-term progression was estimated from overlapping line scans recorded with a time-domain OCT (TD-OCT) instrument (OCT1 or OCT3; Carl Zeiss Meditec, Dublin, CA, USA) along the horizontal meridian crossing the fovea. Post-acquisition processing used custom programs (MATLAB version 7.5; MathWorks, Natick, MA, USA) and raw data of each longitudinal reflectivity profile (LRP). For both SD-OCT and TD-OCT line scans, overlapping segments of LRPs were digitally joined to create 60 degrees wide OCTs centered on the fovea. For TD-OCT, multiple scans taken for each region of interest were considered, and LRPs from the two highest-quality scans were averaged. For both SD-OCT and TD-OCT, segmentation analysis was performed on each LRP to measure the thickness of the outer nuclear layer (ONL). The hyposcattering ONL was defined between the hyperscattering layer attributed to outer plexiform layer (OPL) and the hyperscattering outer limiting membrane (OLM) and included the anatomic layers of both ONL and Henle fiber layer (HFL). Limits of agreement and bias between comparisons of SD-OCT and TD-OCT data obtained decades apart have been published.25 Outer retinal sublaminae were segmented only from SD-OCT data with better axial resolution. Four major sublaminae considered were: (1) a hyper-reflective layer near the junction of inner and outer segments; (2) a hyper-reflective layer near the interface between cone outer segments (COS) and contact cylinder (extrafoveal locations) or apical processes (foveal locations) of the RPE; (3) a hyper-reflective layer near the interface between rod outer segments (ROS) and RPE apical processes; and (4) a hyper-reflective layer near the interface between the basal RPE and Bruch membrane. COS length was defined from (1) to (2), ROS length from (1) to (3), and the combined thickness of the outer segments and subretinal space from (1) to (4). Overlapping three-dimensional SD-OCT raster scans were used for ultra-wide-angle topographic analysis.22 In brief, LRPs making up the OCT scans were aligned by straightening the major RPE reflection. En face images of integrated backscatter intensity were generated, and LRPs were allotted to regularly spaced bins in a rectangular coordinate system centered at the fovea. The waveforms in each bin were aligned, averaged, and segmented. Missing data were interpolated bilinearly; thickness values were mapped to a pseudo-color scale; and fundus landmarks were overlaid for reference. 
Results
Retained Function Despite Chronic Retinal Detachment
Data from both eyes of 17 patients with BVMD (7 families) were available (see the Table). Ages at first visit ranged from 6 to 61 years, and a subset of 7 patients were followed long term (15.5 ± 6.4 years). The majority (20 of 34, 59%) of eyes at the first visit had best corrected visual acuity (BCVA) of 0.2 logMAR (20/30 Snellen equivalent) or better (Fig. 1A), consistent with previous clinical impressions of relatively retained vision despite substantial foveal lesions.27,28 Over the long term, BCVA was lost slowly at the average rate of 0.02 logMAR/year (corresponding to loss of 1 Early Treatment Diabetic Retinopathy Study [ETDRS] letter per year) across the 14 eyes with available longitudinal data (see Fig. 1A). Relatively retained acuity that showed slow progression would be counterintuitive considering the severe degenerative consequences of experimental retinal detachment on photoreceptors.29 Therefore, we investigated details of the visual function in eyes that showed subretinal fluid, but retained foveal fixation thus allowing use of perimetric sensitivity. 
Figure 1.
 
Visual function and serous detachment in Best vitelliform macular dystrophy. (A) Best corrected visual acuity as a function of age in patients with monoallelic BEST1 mutations. Connected symbols represent eyes with follow-up. (B) Horizontal OCT from the right eye of patient F1/P2 demonstrating 0 logMAR visual acuity in an eye with a large serous retinal detachment involving the fovea. Inset, NIR-RAFI image showing the location of the OCT in the eye with pseudo-hypopyon stage. (C) Foveal light-adapted cone sensitivity loss in eyes with foveal serous detachment. Eyes with better acuity have better sensitivity. (D) Rod and cone sensitivity losses in parafoveal areas with serous detachment. A, C, D Gray symbols or bars represent eyes with worse than 0.2 logMAR acuity.
Figure 1.
 
Visual function and serous detachment in Best vitelliform macular dystrophy. (A) Best corrected visual acuity as a function of age in patients with monoallelic BEST1 mutations. Connected symbols represent eyes with follow-up. (B) Horizontal OCT from the right eye of patient F1/P2 demonstrating 0 logMAR visual acuity in an eye with a large serous retinal detachment involving the fovea. Inset, NIR-RAFI image showing the location of the OCT in the eye with pseudo-hypopyon stage. (C) Foveal light-adapted cone sensitivity loss in eyes with foveal serous detachment. Eyes with better acuity have better sensitivity. (D) Rod and cone sensitivity losses in parafoveal areas with serous detachment. A, C, D Gray symbols or bars represent eyes with worse than 0.2 logMAR acuity.
A representative example of a BVMD eye with a large vitelliform lesion but normal visual acuity of 0 logMAR and foveal fixation is F1/P2 at age 14 years (Fig. 1B). En face imaging (see Fig. 1B, inset) shows a pseudohypopyon stage with autofluorescent material accumulated at the inferior aspect of the lesion. Cross-sectional imaging along the horizontal meridian shows a large serous detachment extending from approximately 11 degrees temporal to approximately 5 degrees nasal to the fovea. There were six eyes with similar serous detachments and foveal fixation. To better understand the consequence of the chronic retinal detachment on foveal function, we measured light-adapted sensitivities at the fovea. CSL at the fovea ranged from 4 to 5 decibel (dB) in the eyes with 0.2 logMAR or better acuity, to 10 to 16 dB in the eyes with worse than 0.2 logMAR acuity (Fig. 1C). 
Considering there are at least 4 sources of the 11-cis-retinal chromophore required for rod and cone vision,3032 we next asked whether rod and cone photoreceptor function are differentially affected in extrafoveal regions of eyes with chronic retinal detachment but retained foveal fixation. In 3 eyes with retained visual acuity, there were 41 extrafoveal locations that corresponded to retinal detachment, whereas in 3 eyes with greater acuity loss, there were 19 such locations. In these regions, RSL were substantially greater than CSL at the great majority of retinal locations (Fig. 1D). Greater rod than cone dysfunction associated with detached locations in BVMD was similar to findings in recessive bestrophinopathies11 and could be explained by the dominant source of visual chromophore originating from the retina for cones as opposed to the visual chromophore originating from the RPE for rods.3032 
Microstructural Defects in Clinically Uninvolved Extralesional Retina
To evaluate the retinal microstructure in the clinically uninvolved retinal areas (outside of macular lesions and outside of rare satellite lesions) of patients with BVMD, two key subcellular photoreceptor features were initially assessed: (1) the ONL thickness where rod and cone photoreceptor nuclei reside, and (2) the distance between the junction of inner and outer segments (IS/OS) and the RPE, which would encompass the length of OS plus the subretinal space (Figs. 2A, B, insets). Both features were mapped across an ultra-wide (∼80°) expanse of retina in each eye (Figs. 2A, 2B). As demonstrated in a representative healthy eye, ONL thickness was largest at the fovea with a gradual fall-off with eccentricity (see Fig. 2A). ONL topography in the patient F3/P2 with BVMD was similar to normal but some retinal regions tended to show mild thickening (see Fig. 2B). The normal IS/OS to RPE distance was also largest at the fovea with fast fall-off to parafovea and a nearly homogeneous distribution throughout the rest of the retina (see Fig. 2A). In the representative patient F3/P2 with BVMD, IS/OS to RPE distance was larger than normal throughout the retina (see Fig. 2B). 
Figure 2.
 
Ultra-wide field topography of outer retinal structure in BVMD. (A, B) Topographical maps of ONL thickness (gray map, center) and IS/OS to RPE distance (pseudocolor map, right) obtained from OCT scans (left) in a normal subject and in patient F3/P2. ONL is the major hyposcattering layer on the OCT, IS/OS and RPE peaks are highlighted with orange and brick red, respectively. Purple represents indeterminate regions. (C) Quantitation of the ONL thickness and IS/OS to RPE distance along the two cardinal meridians, horizontal and vertical, crossing the fovea. Black traces are data from individual BVMD eyes, green lines delimit the normal range. N, I, S, and T represent nasal, inferior, superior, and temporal retina, respectively.
Figure 2.
 
Ultra-wide field topography of outer retinal structure in BVMD. (A, B) Topographical maps of ONL thickness (gray map, center) and IS/OS to RPE distance (pseudocolor map, right) obtained from OCT scans (left) in a normal subject and in patient F3/P2. ONL is the major hyposcattering layer on the OCT, IS/OS and RPE peaks are highlighted with orange and brick red, respectively. Purple represents indeterminate regions. (C) Quantitation of the ONL thickness and IS/OS to RPE distance along the two cardinal meridians, horizontal and vertical, crossing the fovea. Black traces are data from individual BVMD eyes, green lines delimit the normal range. N, I, S, and T represent nasal, inferior, superior, and temporal retina, respectively.
ONL thickness was quantified in 22 eyes of 11 patients along the horizontal and vertical meridia crossing the fovea (Fig. 2C). When measurable, ONL overlying macroscopically obvious lesions tended to be thinner than normal suggesting photoreceptor degeneration. In extralesional regions, on the other hand, ONL was either normal or mildly thickened. IS/OS to RPE distance is also shown along the two meridians (see Fig. 2C). Majority of the BVMD eyes across the clinically uninvolved retinal areas showed expansion of the distance from IS/OS to the RPE suggesting either elongation of the OS or widening of the subretinal space or both. 
Outer Segment Length and Subretinal Space
To attempt to differentiate among elongation of cone OS, rod OS, or expansion of the subretinal space with interdigitating OS and microvilli of the RPE, we measured corresponding markers from OCT scans at 2 locations at 16 degrees eccentricity in the superior and inferior retina (Fig. 3). Designation of the backscatter peaks on LRPs corresponding to subcellular photoreceptor and RPE components are shown for a representative normal, and 2 patients F4/P1 and F3/P2 with BVMD (see Figs. 3A, 3C). In most BVMD eyes, there was normal or near normal cone OS length in the superior (see Fig. 3B) and inferior (see Fig. 3D) retina. Rod OS length could be normal or elongated, and the distance to the RPE could be normal or extended both in the superior (see Fig. 3B) and inferior (see Fig. 3D) retina. 
Figure 3.
 
Detailed structure of the photoreceptor-RPE interface in BVMD. (A, C) OCT scan and the longitudinal reflectivity profile of a representative normal and two patients with BVMD in the superior and inferior retina locations. Schematic shows the 16 degrees eccentric location (black square) sampled. (B, D) Distances measured from the IS/OS peak to the cone OS tips (COST) representing COS length, to the rod OS tips (ROST) representing ROS length and to the RPE peak representing combination of outer segments, subretinal space, and the RPE thickness in the superior and inferior retina locations. Left panels show absolute thickness, and the right panels show the thickness difference from mean normal values. Gray rectangles delimit the 99th percentile (±2.33 SD) of the normal values for each parameter.
Figure 3.
 
Detailed structure of the photoreceptor-RPE interface in BVMD. (A, C) OCT scan and the longitudinal reflectivity profile of a representative normal and two patients with BVMD in the superior and inferior retina locations. Schematic shows the 16 degrees eccentric location (black square) sampled. (B, D) Distances measured from the IS/OS peak to the cone OS tips (COST) representing COS length, to the rod OS tips (ROST) representing ROS length and to the RPE peak representing combination of outer segments, subretinal space, and the RPE thickness in the superior and inferior retina locations. Left panels show absolute thickness, and the right panels show the thickness difference from mean normal values. Gray rectangles delimit the 99th percentile (±2.33 SD) of the normal values for each parameter.
Functional Consequences of an Expanded Subretinal Space
Rod sensitivities were normal across clinically uninvolved extralesional regions of BVMD retinas; this implied that minor changes in the subretinal space do not result in detectable changes to the primary function of rods, which is to signal dim lights under fully dark-adapted conditions. However, because the bulk of the chromophore for rod cells is thought to originate from RPE cells, we hypothesized that abnormalities at the interdigitation of the outer segments and RPE microvilli may slow down the kinetics of the resupply of chromophore and thus the rate of dark adaptation. In a subset of 4 patients with BVMD , at a macular region 10 degrees nasal to the fovea, we recorded dark-adaptation kinetics of the rod system (Fig. 4). All four patients had near-normal ONL thickness and dark-adapted sensitivities ruling out retinal degeneration. Three of the four patients (F4/P1, F1/P4, and F7/P1), had normal or near normal rod and cone OS thicknesses and normal subretinal space (see Fig. 4A) and they demonstrated normal kinetics of dark-adaptation recovery (see Fig. 4B). One patient (F3/P2) with elongated cone OS, rod OS, and wider subretinal space (see Fig. 4A), demonstrated a substantial slowing of the dark-adaptation recovery rate (see Fig. 4B). These data appear to support a relation between rod dark-adaptation recovery rate and the abnormality of the subretinal space. However, it is important to note the results from a fifth patient (F3/P1) demonstrating substantial thinning of the ONL (see Fig. 4C) but retaining apparently normal distances of IS/OS to COS, ROS, and RPE. Dark-adapted sensitivities of F3/P1 were elevated by more than a log unit, and there was substantial slowing of the dark-adaptation rate (see Fig. 4D). This retinal-degeneration-associated abnormality in dark-adaptation rate was similar to an effect previously described in patients with ABCA4-associated Stargardt disease33 and BEST1-associated autosomal recessive bestrophinopathy.11 Thus, it is important to note that dark-adaptation kinetic abnormalities could have multiple causes but the combination of normal ONL thickness, normal dark-adapted sensitivities, and slowed kinetics likely places the physiological defect measured in F3/P2 at the abnormal RPE-PR interface. 
Figure 4.
 
Relation of retinal ultrastructure and dark-adaptation kinetics. (A) Outer retinal ultrastructure at 10 degrees nasal to the fovea (schematic, black square) shows the thickness difference from mean normal for COS and ROS length and IS/OS to RPE distance similar to Figures 3B and 3D. Four patients had normal ONL thickness whereas one patient (F3/P2) had abnormally thinned ONL. (B) Dark-adaptation kinetics following a transient adapting light presented at time zero. Data from four patients (unfilled circles) are shown in comparison to normal data (filled gray circles). Symbols identify the individual patients plotted in panel A. (C) OCT scan of patient F3/P1-OS at the locus evaluated with dark-adaptation kinetics (white rectangle) demonstrating substantially diminished ONL thickness compared to a representative normal. (D) Dark-adaptation kinetics showing elevated thresholds before the adapting light, and exceedingly slow recovery timecourse after the adapting light.
Figure 4.
 
Relation of retinal ultrastructure and dark-adaptation kinetics. (A) Outer retinal ultrastructure at 10 degrees nasal to the fovea (schematic, black square) shows the thickness difference from mean normal for COS and ROS length and IS/OS to RPE distance similar to Figures 3B and 3D. Four patients had normal ONL thickness whereas one patient (F3/P2) had abnormally thinned ONL. (B) Dark-adaptation kinetics following a transient adapting light presented at time zero. Data from four patients (unfilled circles) are shown in comparison to normal data (filled gray circles). Symbols identify the individual patients plotted in panel A. (C) OCT scan of patient F3/P1-OS at the locus evaluated with dark-adaptation kinetics (white rectangle) demonstrating substantially diminished ONL thickness compared to a representative normal. (D) Dark-adaptation kinetics showing elevated thresholds before the adapting light, and exceedingly slow recovery timecourse after the adapting light.
Long-Term Natural History of Retinal Structure
Among the outer retinal abnormalities in clinically uninvolved retina, was minor ONL thickening observed in some retinal locations of some patients with BVMD (see Fig. 2). To better understand the temporal development of this finding, we took advantage of the long-term natural history of retinal structure in a subset of 6 patients with BVMD who were followed with OCT over nearly 2 decades (Fig. 5). Qualitatively, in five of six patients, there were relatively small changes; central lesions showed minor changes, and clinically uninvolved extralesional areas appeared to be unchanged (see Fig. 5). An important exception was F1/P3, who showed formation of an extra-macular satellite lesion temporal to the fovea. Next, we quantified the ONL thickness across the horizontal meridian crossing the fovea. Overlying the central lesions, ONL thickness was reduced implying a progressive photoreceptor degeneration. Altered visibility of the HFL secondary to lesion changes could possibly contribute to the measured ONL but does not fully account for large magnitude of ONL thinning seen in F4/P1-OD and F1/P4-OD. ONL thinning also occurred over the newly formed satellite lesion in F1/P3-OS. Changes in extralesional regions were mostly within the variability observed with similar ultra-long-term evaluations25,26; however, it was notable that there was a tendency toward ONL thickening over time. In some patients and some retinal locations (F1/P4-OD and F1/P5-OS), ONL thickness moved from being near the upper limit of normal to being significantly hyperthick (see double arrows in Fig. 5); in other patients and other retinal locations, there was evidence for relative thickening of ONL albeit remaining within normal limits (see single arrows in Fig. 5). 
Figure 5.
 
Long-term changes in retinal structure. (A) Long-term (17–21 years) follow-up of younger (20–23 years old at first visit) patients with BVMD. (B) Long-term (10–20 years) follow-up of older (34–47 years old at first visit) patients with BVMD. In each panel, OCT scans along the horizontal meridian crossing the fovea are shown at two ages. ONL thickness is quantified (gray trace first visit and black trace last visit) and compared to the normal range. Bar graphs show ONL thickness change (last minus first) sampled across the retina. Double arrows mark regions of thickening beyond the normal range and single arrows mark regions of thickening within the normal range.
Figure 5.
 
Long-term changes in retinal structure. (A) Long-term (17–21 years) follow-up of younger (20–23 years old at first visit) patients with BVMD. (B) Long-term (10–20 years) follow-up of older (34–47 years old at first visit) patients with BVMD. In each panel, OCT scans along the horizontal meridian crossing the fovea are shown at two ages. ONL thickness is quantified (gray trace first visit and black trace last visit) and compared to the normal range. Bar graphs show ONL thickness change (last minus first) sampled across the retina. Double arrows mark regions of thickening beyond the normal range and single arrows mark regions of thickening within the normal range.
Onset of Extra-Macular Satellite Lesions
In nine eyes of five patients, there were extra-macular satellite lesions at one or more visits. Unexpectedly, in both eyes of one patient, onset of several de novo extra-macular satellite lesions was observed in retinal regions where there was no evidence of a lesion at an earlier visit. In F1/P4-OD, NIR-RAFI at ages 29 and 37 years showed only a macular lesion (Fig. 6A). At age 43 years, however, several small lesions had formed along the superior arcade and OCTs were consistent with development of local outer retinal deposits where none existed previously (Fig. 6B). IS/OS-RPE thickness topography performed across an ultra-wide extent of retina at age 37 years showed the existence of an arcuate region of subclinical abnormality (IS/OS-RPE distance >10 um greater than normal) at the superior vascular arcade. Several serous detachments developed in this area 6 years later (Fig. 6C). The region around the newly developed serous detachments showed greater abnormality of the IS/OS-RPE distance (see Fig. 6C). In F1/P4-OS, NIR-RAFI at age 29 years showed only a macular lesion (Fig. 6D). At age 37 years, a satellite lesion had formed superior to the optic nerve head near the eccentricity of the vascular arcades. At age 43 years, a second satellite lesion formed superotemporal to the macula. OCTs were consistent with the development of a local serous detachment where none existed previously (Fig. 6E). IS/OS-RPE thickness topography showed the existence of an arcuate region of subclinical abnormality (IS/OS-RPE distance >20 um greater than normal) along a band at the superior vascular arcades, which appear to precede the onset of the lesion (Fig. 6F). These rare results appear to support the hypothesis that clinically obvious outer retinal deposits and serous detachments may be preceded by subclinical widening of the IS/OS-RPE distance. 
Figure 6.
 
Late development of satellite lesions in both eyes of patient F1/P4. (A, D) NIR-RAFI results at ages 29, 37, and 43 years show development of de novo lesions (pink outlines) at age 43 years in Panel A and at ages 37 and 43 years in Panel D. (B, E) Representative OCTs demonstrate serous detachments in retinal locations (arrows in A and D) that were previously attached. (C, F) Ultrawide-field topography of the IS/OS to RPE distance shows arcuate regions of hyper-thickening in the superior paramacular retina at age 37 years preceding the development of de novo serous detachments 6 years later. Purple represents regions with indeterminate IS/OS to RPE distance.
Figure 6.
 
Late development of satellite lesions in both eyes of patient F1/P4. (A, D) NIR-RAFI results at ages 29, 37, and 43 years show development of de novo lesions (pink outlines) at age 43 years in Panel A and at ages 37 and 43 years in Panel D. (B, E) Representative OCTs demonstrate serous detachments in retinal locations (arrows in A and D) that were previously attached. (C, F) Ultrawide-field topography of the IS/OS to RPE distance shows arcuate regions of hyper-thickening in the superior paramacular retina at age 37 years preceding the development of de novo serous detachments 6 years later. Purple represents regions with indeterminate IS/OS to RPE distance.
Discussion
Visual Function in BVMD
Clinical studies in BVDM during the pre-molecular era,34,35 as well as large series performed more recently in molecularly confirmed patients,3638 have shown many patients over a substantial range of ages to have at least one eye with BCVA of 20/40 or better. This level of BCVA would be consistent with retained cone photoreceptor function in many patients with clinically obvious and often chronic serous detachments of the fovea.28 In our cohort, there were BVMD eyes with 20/20 vision and fixation at the fovea which was chronically detached from the underlying RPE. Taking the previously published results together with the current findings, the only conclusion that can be reached is that in BVMD, survival and function of foveal cone photoreceptors are not dependent on their attachment to the RPE cells. 
BCVA is a coarse measure of spatial vision and does not scale linearly with photoreceptor degeneration at least for the loss of the first approximately 50%.3941 Perimetric light sensitivity provides another measure of visual function and allows sampling of distinct retinal locations surrounding the fovea. Previously, fundus-controlled microperimetry has shown foveal and parafoveal sensitivity losses with retinal lesions in patients with BVMD38,4244; however, tests were performed under mesopic conditions and the relative contribution of rod versus cone photoreceptors losses were not known. In a subset of eyes retaining stable foveal fixation, we performed light- and dark-adapted perimetry and determined that at retinal loci with chronic serous detachments rod sensitivity losses tended to be substantially higher than cone sensitivity losses. Relatively greater involvement of rod sensitivity or low luminance visual acuity has previously been demonstrated in central serous retinopathy (CSR)45,46 but we are not aware of investigations of direct colocalized comparison of rod and cone function in BVMD or CSR. Publications reporting histopathology from BVMD eye donors have not quantitatively evaluated the comparative involvement of rod and cone photoreceptors.4753 It remains to be determined whether the observed loss of rod function in central lesion areas of BVMD corresponds to degeneration or dysfunction of rod photoreceptors, or to remodeling of postreceptoral connections.54 
Thickening of the Outer Nuclear Layer
Human IRDs and their animal models involve progressive degeneration of the photoreceptors, which is reflected by the thinning of the ONL readily measurable on histology.55,56 Soon after development of the OCT,57 our group was the first to recognize that ONL thickness could be measured noninvasively in humans and animals,58,59 and progression rates based on loss of photoreceptors could be quantitatively inferred in vivo from serial measurements of the ONL thickness over time.26,60 It is less appreciated that counterintuitive thickening can sometimes precede the ONL thinning.61 A mild ONL thickening can be chronic or a transient stage in a continuum and it has been detected at the foveas of patients with choroideremia,62 periphery of patients with NPHP5- or CEP290-associated Leber congenital amaurosis (LCA),22 and surrounding the macular drusen in age-related macular degeneration (AMD).63 Thickened ONL has also been observed in animals as a consequence of interventions or mild disease states.11,64,65 More recently, thickening of ONL upon gene augmentation therapy was seen.66 Our current work showed that mild ONL thickening is detectable across the clinically normal-appearing retinas of many patients with BVMD, and this feature can slowly be accentuated over decades in otherwise normal retinal areas. Our work is consistent with “apparent thickening” of the ONL outside lesion areas and in previtelliform disease stages previously observed in some patients with BVMD.67 It is unlikely that thickened ONL observed across diverse IRDs and AMD represent the same exact underlying pathophysiological cause; however, involvement of subclinical edema due to abnormalities at the RPE-PR interface or sub-threshold signaling of photoreceptor stress to glial cells can be postulated in BVMD. 
Outer Segment and RPE Interface in Clinically Uninvolved Extralesional Areas
Clinically obvious serous detachments of the retina from the RPE have been well described in BVMD.18,68 This grossly detectable pathology is consistent with the recent understanding that the primary molecular defect acts at the RPE-PR interface in the canine model10,11 despite Bestrophin-1 being normally localized to the basolateral plasma membrane of the RPE.12,13 What remains less clear is the state of the photoreceptor outer segments and RPE across wide expanses of clinically uninvolved extralesional areas of the retina in patients with BVMD. Previous investigations to evaluate the earliest disease features in BVMD have resulted in some controversy. Some qualitative studies have suggested subclinical abnormalities at the outer retina,6971 but quantitative studies have come to opposing conclusions. One study measured “photoreceptor equivalent thickness” or “outer segment equivalent length” between the “IS/OS junction” and the “inner surface of the RPE” and found that distance to be on average 6.5 um wider in patients with BVMD compared to controls.52,72 Another study measured the “length of outer segments” between the “IS/OS junction” and the “RPE1, outer segment/RPE interface” and found no difference between BVMD and controls43 and controversy ensued.73,74 Using our interpretation of OCT peaks in human eyes,23 measurements of the earlier study52,72 would closely relate to what we have labeled ROS length in the current study, and that of the latter study43 would correspond to what we have labeled COS length. At the superior and inferior perimacular regions, we found greater numbers of eyes with lengthening of the ROS than those with lengthening of the COS in patients with BVMD (see Fig. 3). Thus, our results confirm both previous conclusions and help clarify the source of the apparent controversy in the literature. 
Understanding of the microscopic details of the minor structural abnormalities in some BVMD eyes well away from central lesions in clinically normal-appearing retina remains elusive. It has been suggested that RPE-PR interface is filled with extremely long and/or unphagocytized photoreceptor outer segments52 and that may be true. Extrapolation from the results in dogs with biallelic BEST1 mutations would suggest a developmental abnormality of the RPE microvilli preceding detectable disease onset.11 Studies in dogs heterozygous for BEST1 mutations could potentially distinguish between these hypotheses in the future. More pragmatically, do these micron-level subclinical abnormalities have any consequence to the progression of disease or loss of vision that BVMD patients may experience? To answer this question is challenging due to the slow progression of disease and limited longitudinal studies with higher resolution cross-sectional techniques. However, in both eyes of one patient, we showed de novo formation of clinically obvious lesions in the exact area of the retina that 6 years earlier showed the largest subclinical RPE-PR abnormality but no lesions. In another patient, we showed dark-adaptation kinetic abnormalities corresponding to the location with a subclinical RPE-PR abnormality. If these anecdotal findings are representative of the progression and vision loss experienced in BVMD, it would be justifiable to treat such retinal areas with subclinical disease assuming a safe and effective treatment becomes available in the future. 
There has been increasing evidence that measurable structural changes occur in the outer retina with light exposure.52,7583 For the current work, all OCT imaging was performed in dark-adapted eyes. It remains to be determined whether previously hypothesized light dependent changes to BVMD outer segment lengths52,73 can be confirmed. 
Outcome Measures for Clinical Trials of BEST1 BVMD
Our results support choices of outcome measures for clinical trials attempting to improve retinal structure and visual function. We showed relatively retained BCVA and relatively large losses of scotopic light sensitivity. In AMD with a scotopic deficit,84 low-luminance visual acuity (LLVA)85 has been found to be a simple but informative outcome.86,87 In the current study, we did not record LLVA, and we are not aware of literature measuring LLVA in BVMD. However, patients with CSR have shown large reductions in LLVA despite retaining good BCVA.46 Assuming comparability of dysfunction resulting from serous retinal detachments in CSR and BVMD, future studies should evaluate LLVA in BVMD as a prerequisite for its potential use as an outcome measure in addition to standard BCVA. 
Perimetric methods provide topographic distribution of light sensitivity and can allow comparison of treated areas to neighboring untreated regions in localized interventions, such as subretinal gene therapy.60 Use of light-adapted or dark-adapted conditions allows direct comparison of cone and rod function as was done in the current study. However, standard perimetric methods require foveal fixation which may not be attainable in some patients with BVMD. Thus “microperimetry” methods performed with real time tracking of the retina is required. Measurement of cone function with microperimetry is challenging and we are aware of only one instrument that provides testing with the standard photopic background.88 Measurement of rod function with microperimetry is also challenging due to the limited dynamic range of stimuli available in all devices.8991 Previous studies in BVMD have used microperimetry under mesopic conditions which do not allow distinction of rod and cone function.38,4244 For a future clinical trial, it would be important to use a microperimetric method, the results of which can be interpreted confidently in terms of the function of the underlying photoreceptor system. 
En face imaging methods provide convenient analytics to measure changes in lesion appearance and extent as part of the natural history of disease or interventions. Historically, color fundus photographs were used to describe the evolution of BVMD lesions14,35 but advent of imaging with short-wavelength autofluorescence (SW-AF) showed a specific hyperintense signal within vitelliform lesions.9295 However, conventional SW-AF is performed with a high intensity excitation light which could, at least in principle, accelerate retinal disease.96 Therefore, we developed an RAFI method using NIR excitation.21 NIR-RAFI can provide en face information regarding RPE health with some similarities to the standard SW-AF results.97,98 In the case of BVMD, NIR-RAFI can be more sensitive to earliest disease features,99 but unlike the ABCA4 form of macular degeneration,33 extralesional areas in BVMD do not show abnormal increases in SW-AF and NIR-RAFI signals.67,99 In the current work, we used NIR-RAFI to delineate not only the gross macular lesions but also de novo development of small satellite lesions. Similarly, NIR-RAFI can form an important outcome measure to provide information regarding RPE health with comfortable lights and a short examination time without undue light hazard potential. 
Cross sectional imaging with OCT is a key outcome for BVMD clinical trials. The extent of the vitelliform lesions can be quantified. Additionally, current results strongly suggest that hyperthickening of the ONL and widening of the distance between the IS/OS and the RPE may be the only subclinical abnormalities in paralesional retinal areas that can be evaluated quantitatively for efficacy and safety experimental interventions in clinical trials. 
Acknowledgments
Supported by IVERIC Bio, Inc., NEI R01EY06855, Foundation Fighting Blindness, unrestricted funds from Research to Prevent Blindness, and the Sanford and Susan Greenberg End Blindness Outstanding Achievement Prize. 
A.V.C., S.G.J., K.E.G., G.D.A., and W.A.B. are listed as co-inventors on two US Patent Applications related to treating bestrophinopathies. 
Disclosure: A.V. Cideciyan, IVERICBIO (F, P); S.G. Jacobson, IVERICBIO (F, P); M. Swider, None; A. Sumaroka, None; R. Sheplock, None; A.K. Krishnan, None; A.V. Garafalo, None; K.E. Guziewicz, IVERICBIO (F, P); G.D. Aguirre, IVERICBIO (F, P); W.A. Beltran, IVERICBIO (F, P); E. Heon, None 
References
Best F. Ueber eine hereditare Maculaaffektion: beiträge zur Vererbungslehre. Z Augenheilkd. 1905; 13: 199–212.
Petrukhin K, Koisti MJ, Bakall B, et al. Identification of the gene responsible for best macular dystrophy. Nat Genet. 1998; 19: 241–247. [CrossRef] [PubMed]
Marquardt A, Stöhr H, Passmore LA, Krämer F, Rivera A, Weber BHF. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). Hum Mol Genet. 1998; 7: 1517–1525. [CrossRef] [PubMed]
Yardley J, Leroy BP, Hart-Holden N, et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci. 2004; 45: 3683–3689. [CrossRef] [PubMed]
Schatz P, Klar J, Andréasson S, Ponjavic V, Dahl N. Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet. 2006; 27: 51–56. [CrossRef] [PubMed]
Burgess R, Millar ID, Leroy BP, et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet. 2008; 82: 19–31. [CrossRef] [PubMed]
Boon CJF, Klevering BJ, Leroy BP, Hoyng CB, Keunen JEE, den Hollander AI. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res. 2009; 28: 187–205. [CrossRef] [PubMed]
Marmorstein AD, Cross HE, Peachey NS. Functional roles of bestrophins in ocular epithelia. Prog Retin Eye Res. 2009; 28: 206–226. [CrossRef] [PubMed]
Johnson AA, Guziewicz KE, Lee CJ, et al. Bestrophin 1 and retinal disease. Prog Retin Eye Res. 2017; 58: 45–69. [CrossRef] [PubMed]
Guziewicz KE, Sinha D, Gomez NM, et al. Bestrophinopathy: An RPE-photoreceptor interface disease. Prog Retin Eye Res. 2017; 58: 70–88. [CrossRef] [PubMed]
Guziewicz KE, Cideciyan AV, Beltran WA, et al. BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proc Natl Acad Sci USA. 2018; 115: E2839–E2848. [CrossRef] [PubMed]
Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci USA. 2000; 97: 12758–12763. [CrossRef] [PubMed]
Mullins RF, Kuehn MH, Faidley EA, Syed NA, Stone EM. Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease. Invest Ophthalmol Vis Sci. 2007; 48: 3372–3380. [CrossRef] [PubMed]
Deutman AF. Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch Ophthalmol. 1969; 81: 305–316. [CrossRef] [PubMed]
Ji C, Li Y, Kittredge A, et al. Investigation and restoration of BEST1 activity in patient-derived RPEs with dominant mutations. Sci Rep. 2019; 9: 19026. [CrossRef] [PubMed]
Sinha D, Steyer B, Shahi PK, et al. Human iPSC modeling reveals mutation-specific responses to gene therapy in a genotypically diverse dominant maculopathy. Am J Hum Genet. 2020; 107: 278–292. [CrossRef] [PubMed]
Liu J, Taylor RL, Baines RA, et al. Small molecules restore Bestrophin 1 expression and function of both dominant and recessive Bestrophinopathies in patient-derived retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2020; 61: 28. [CrossRef] [PubMed]
Pianta MJ, Aleman TS, Cideciyan AV, et al. In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res. 2003; 76: 203–211. [CrossRef] [PubMed]
Jacobson SG, Voigt WJ, Parel JM, et al. Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa. Ophthalmology. 1986; 93: 1604–1611. [CrossRef] [PubMed]
Cideciyan AV, Krishnan AK, Roman AJ, Sumaroka A, Swider M, Jacobson SG. Measures of function and structure to determine phenotypic features, natural history, and treatment outcomes in inherited retinal diseases. Annu Rev Vis Sci. 2021; 7: 747–772. [CrossRef] [PubMed]
Cideciyan AV, Swider M, Aleman TS, et al. Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations. J Opt Soc Am A. 2007; 24: 1457–1457. [CrossRef]
Cideciyan AV, Rachel RA, Aleman TS, et al. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: Generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. Hum Mol Genet. 2011; 20: 1411–1423. [CrossRef] [PubMed]
Cideciyan AV, Hufnagel RB, Carroll J, et al. Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther. 2013; 24: 993–1006. [CrossRef] [PubMed]
Jacobson SG, McGuigan DB, Sumaroka A, et al. Complexity of the class B phenotype in autosomal dominant retinitis pigmentosa due to rhodopsin mutations. Invest Ophthalmol Vis Sci. 2016; 57: 4847–4858. [CrossRef] [PubMed]
Calzetti G, Levy RA, Cideciyan AV, et al. Efficacy outcome measures for clinical trials of USH2A caused by the common c.2299delG mutation. Am J Ophthalmol. 2018; 193: 114–129. [CrossRef] [PubMed]
Cideciyan AV, Jacobson SG, Roman AJ, et al. Rod function deficit in retained photoreceptors of patients with class B Rhodopsin mutations. Sci Rep. 2020; 10: 12552–12552. [CrossRef] [PubMed]
Augstburger E, Ores R, Mohand-Said S, et al. Outer retinal alterations associated with visual outcomes in Best vitelliform macular dystrophy. Am J Ophthalmol. 2019; 208: 429–437. [CrossRef] [PubMed]
Gattoussi S, Boon CJF, Freund KB. Maintenance of good visual acuity in Best disease associated with chronic bilateral serous macular detachment. Retin Cases Brief Rep. 2020; 14: 1–5. [CrossRef] [PubMed]
Guerin CJ, Lewis GP, Fisher SK, Anderson DH. Recovery of photoreceptor outer segment length and analysis of membrane assembly rates in regenerating primate photoreceptor outer segments. Invest Ophthalmol Vis Sci. 1993; 34: 175–183. [PubMed]
Cideciyan AV, Haeseleer F, Fariss RN, et al. Rod and cone visual cycle consequences of a null mutation in the 11-cis-retinol dehydrogenase gene in man. Vis Neurosci. 2000; 17: 667–678. [CrossRef] [PubMed]
Palczewski K, Kiser PD. Shedding new light on the generation of the visual chromophore. Proc Natl Acad Sci USA. 2020; 117: 19629–19638. [CrossRef] [PubMed]
Kim HJ, Zhao J, Sparrow JR. Vitamin A aldehyde-taurine adduct and the visual cycle. Proc Natl Acad Sci USA. 2020; 117: 24867–24875. [CrossRef] [PubMed]
Cideciyan AV, Aleman TS, Swider M, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: A reappraisal of the human disease sequence. Hum Mol Genet. 2004; 13: 525–534. [CrossRef] [PubMed]
Mohler CW, Fine SL. Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology. 1981; 88: 688–692. [CrossRef] [PubMed]
Clemett R. Vitelliform dystrophy: long-term observations on New Zealand pedigrees. Aust N Z J Ophthalmol. 1991; 19: 221–227. [CrossRef] [PubMed]
Cohn AC, Turnbull C, Ruddle JB, et al. Best's macular dystrophy in Australia: phenotypic profile and identification of novel BEST1 mutations. Eye (Lond). 2011; 25: 208–217. [CrossRef] [PubMed]
Booij JC, Boon CJ, van Schooneveld MJ, et al. Course of visual decline in relation to the BEST1 genotype in vitelliform macular dystrophy. Ophthalmology. 2010; 117: 1415–1422. [CrossRef] [PubMed]
Battaglia Parodi M, Castellino N, Iacono P, et al. Microperimetry in Best vitelliform macular dystrophy. Retina. 2018; 38: 841–848. [CrossRef] [PubMed]
Geller AM, Sieving PA. Assessment of foveal cone photoreceptors in Stargardt's macular dystrophy using a small dot detection task. Vision Res. 1993; 33: 1509–1524. [CrossRef] [PubMed]
Ratnam K, Carroll J, Porco TC, Duncan JL, Roorda A. Relationship between foveal cone structure and clinical measures of visual function in patients with inherited retinal degenerations. Invest Ophthalmol Vis Sci. 2013; 54: 5836–5847. [CrossRef] [PubMed]
Foote KG, Loumou P, Griffin S, et al. Relationship between foveal cone structure and visual acuity measured with adaptive optics scanning laser ophthalmoscopy in retinal degeneration. Invest Ophthalmol Vis Sci. 2018; 59: 3385–3393. [CrossRef] [PubMed]
Jarc-Vidmar M, Popovic P, Hawlina M. Mapping of central visual function by microperimetry and autofluorescence in patients with Best's vitelliform dystrophy. Eye (Lond). 2006; 20: 688–696. [CrossRef] [PubMed]
Kay DB, Land ME, Cooper RF, et al. Outer retinal structure in Best vitelliform macular dystrophy. JAMA Ophthalmol. 2013; 131: 1207–1215. [CrossRef] [PubMed]
Parodi MB, Iacono P, Del Turco C, Triolo G, Bandello F. Functional assessment of the fundus autofluorescence pattern in Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol. 2016; 254: 1297–1302. [CrossRef] [PubMed]
Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC. Retinal dysfunction in central serous retinopathy. Eye (Lond). 1987; 1(Pt 1): 120–125. [PubMed]
Fujita K, Shinoda K, Matsumoto CS, et al. Low luminance visual acuity in patients with central serous chorioretinopathy. Clin Exp Optom. 2013; 96: 100–105. [CrossRef] [PubMed]
Frangieh GT, Green WR, Fine SL. A histopathologic study of Best's macular dystrophy. Arch Ophthalmol. 1982; 100: 1115–1121. [CrossRef] [PubMed]
Weingeist TA, Kobrin JL, Watzke RC. Histopathology of Best's macular dystrophy. Arch Ophthalmol. 1982; 100: 1108–1114. [CrossRef] [PubMed]
O'Gorman S, Flaherty WA, Fishman GA, Berson EL. Histopathologic findings in Best's vitelliform macular dystrophy. Arch Ophthalmol. 1988; 106: 1261–1268. [CrossRef] [PubMed]
Mullins RF, Oh KT, Heffron E, Hageman GS, Stone EM. Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. Arch Ophthalmol. 2005; 123: 1588–1594. [CrossRef] [PubMed]
Zhang Q, Small KW, Grossniklaus HE. Clinicopathologic findings in Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol. 2011; 249: 745–751. [CrossRef] [PubMed]
Abramoff MD, Mullins RF, Lee K, et al. Human photoreceptor outer segments shorten during light adaptation. Invest Ophthalmol Vis Sci. 2013; 54: 3721–3728. [CrossRef] [PubMed]
Bonilha VL, Bell BA, DeBenedictis MJ, Hagstrom SA, Fishman GA, Hollyfield JG. Cellular changes in retinas from patients with BEST1 mutations. Front Cell Dev Biol. 2020; 8: 573330. [CrossRef] [PubMed]
Fisher SK, Lewis GP, Linberg KA, Verardo MR. Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog Retin Eye Res. 2005; 24: 395–431. [CrossRef] [PubMed]
LaVail MM. Analysis of neurological mutants with inherited retinal degeneration. Friedenwald lecture. Invest Ophthalmol Vis Sci. 1981; 21: 638–657. [PubMed]
Milam AH, Li ZY, Fariss RN. Histopathology of the human retina in retinitis pigmentosa. Prog Ret Eye Res. 1998; 17: 175–205.
Huang D, Swanson E, Lin C, et al. Optical coherence tomography. Science. 1991; 254: 1178–1181. [CrossRef] [PubMed]
Jacobson SG, Buraczynska M, Milam AH, et al. Disease expression in X-linked retinitis pigmentosa caused by a putative null mutation in the RPGR gene. Invest Ophthalmol Vis Sci. 1997; 38: 1983–1997. [PubMed]
Huang Y, Cideciyan AV, Papastergiou GI, et al. Relation of optical coherence tomography to microanatomy in normal and rd chickens. Invest Ophthalmol Vis Sci. 1998; 39: 2405–2416. [PubMed]
Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA. 2013; 110: E517–E525. [PubMed]
Jacobson SG, Cideciyan AV. Treatment possibilities for retinitis pigmentosa. N Engl J Med. 2010; 363: 1669–1671. [CrossRef] [PubMed]
Jacobson SG, Cideciyan AV, Sumaroka A, et al. Remodeling of the human retina in choroideremia: Rab escort protein 1 (REP-1) mutations. Invest Ophthalmol Vis Sci. 2006; 47: 4113–4120. [CrossRef] [PubMed]
Sadigh S, Cideciyan AV, Sumaroka A, et al. Abnormal thickening as well as thinning of the photoreceptor layer in intermediate age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013; 54: 1603–1612. [CrossRef] [PubMed]
Beltran WA, Cideciyan AV, Iwabe S, et al. Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci USA. 2015; 112: E5844–E5853. [CrossRef] [PubMed]
Cideciyan AV, Sudharsan R, Dufour VL, et al. Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc Natl Acad Sci USA. 2018; 115: E8547–E8556. [CrossRef] [PubMed]
Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020; 26: 354–359. [CrossRef] [PubMed]
Duncker T, Greenberg JP, Ramachandran R, et al. Quantitative fundus autofluorescence and optical coherence tomography in best vitelliform macular dystrophy. Invest Ophthalmol Vis Sci. 2014; 55: 1471–1482. [CrossRef] [PubMed]
Spaide RF, Noble K, Morgan A, Freund KB. Vitelliform macular dystrophy. Ophthalmology. 2006; 113: 1392–1400. [CrossRef] [PubMed]
Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH. High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol. 2008; 146: 501–507. [CrossRef] [PubMed]
Ferrara DC, Costa RA, Tsang S, Calucci D, Jorge R, Freund KB. Multimodal fundus imaging in Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol. 2010; 248: 1377–1386. [CrossRef] [PubMed]
Querques G, Zerbib J, Santacroce R, et al. The spectrum of subclinical Best vitelliform macular dystrophy in subjects with mutations in BEST1 gene. Invest Ophthalmol Vis Sci. 2011; 52: 4678–4684. [CrossRef] [PubMed]
Kay CN, Abramoff MD, Mullins RF, et al. Three-dimensional distribution of the vitelliform lesion, photoreceptors, and retinal pigment epithelium in the macula of patients with best vitelliform macular dystrophy. Arch Ophthalmol. 2012; 130: 357–364. [CrossRef] [PubMed]
Abramoff MD, Mullins RF, Stone EM. Outer segment length in different Best disease genotypes. JAMA Ophthalmol. 2014; 132: 1152–1153. [CrossRef] [PubMed]
Stepien KE, Kay DB, Carroll J. Outer segment length in different Best disease genotypes–reply. JAMA Ophthalmol. 2014; 132: 1153. [CrossRef] [PubMed]
Uehara F, Matthes MT, Yasumura D, LaVail MM. Light-evoked changes in the interphotoreceptor matrix. Science. 1990; 248: 1633–1636. [CrossRef] [PubMed]
Huang B, Karwoski CJ. Light-evoked expansion of subretinal space volume in the retina of the frog. J Neurosci. 1992; 12: 4243–4252. [CrossRef] [PubMed]
Putting BJ, Zweypfenning RC, Vrensen GF, Oosterhuis JA, van Best JA. Blood-retinal barrier dysfunction at the pigment epithelium induced by blue light. Invest Ophthalmol Vis Sci. 1992; 33: 3385–3393. [PubMed]
Li JD, Govardovskii VI, Steinberg RH. Light-dependent hydration of the space surrounding photoreceptors in the cat retina. Vis Neurosci. 1994; 11: 743–752. [CrossRef] [PubMed]
Bissig D, Berkowitz BA. Light-dependent changes in outer retinal water diffusion in rats in vivo. Mol Vis. 2012; 18: 2561–2577. [PubMed]
Lu R, Levy AM, Zhang Q, Pittler SJ, Yao X. Dynamic near-infrared imaging reveals transient phototropic change in retinal rod photoreceptors. J Biomed Opt. 2013; 18: 106013. [PubMed]
Li Y, Fariss RN, Qian JW, Cohen ED, Qian H. Light-induced thickening of photoreceptor outer segment layer detected by ultra-high resolution OCT imaging. Invest Ophthalmol Vis Sci. 2016; 57: OCT105–OCT111. [CrossRef] [PubMed]
Lu Y, Wang B, Pepperberg DR, Yao X. Stimulus-evoked outer segment changes occur before the hyperpolarization of retinal photoreceptors. Biomed Opt Express. 2017; 8: 38–47. [CrossRef] [PubMed]
Zhang P, Zawadzki RJ, Goswami M, et al. In vivo optophysiology reveals that G-protein activation triggers osmotic swelling and increased light scattering of rod photoreceptors. Proc Natl Acad Sci USA. 2017; 114: E2937–E2946. [PubMed]
Owsley C, Jackson GR, Cideciyan AV, et al. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000; 41: 267–273. [PubMed]
Sunness JS, Rubin GS, Broman A, Applegate CA, Bressler NM, Hawkins BS. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology. 2008; 115: 1480–1488, 1488 e1481-1482. [CrossRef] [PubMed]
Puell MC, Barrio AR, Palomo-Alvarez C, Gomez-Sanz FJ, Clement-Corral A, Perez-Carrasco MJ. Impaired mesopic visual acuity in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012; 53: 7310–7314. [CrossRef] [PubMed]
Terheyden JH, Holz FG, Schmitz-Valckenberg S, et al. Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR. Trials. 2020; 21: 659. [CrossRef] [PubMed]
Palkovits S, Hirnschall N, Georgiev S, Leisser C, Findl O. Test-retest reproducibility of the microperimeter MP3 with fundus image tracking in healthy subjects and patients with macular disease. Transl Vis Sci Technol. 2018; 7: 17. [CrossRef] [PubMed]
Birch DG, Wen Y, Locke K, Hood DC. Rod sensitivity, cone sensitivity, and photoreceptor layer thickness in retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2011; 52: 7141–7147. [CrossRef] [PubMed]
Pfau M, Lindner M, Müller PL, et al. Effective dynamic range and retest reliability of dark-adapted two-color fundus-controlled perimetry in patients with macular diseases. Invest Ophthalmol Vis Sci. 2017; 58: BIO158–BIO167. [CrossRef] [PubMed]
Krishnan AK, Roman AJ, Swider M, Jacobson SG, Cideciyan AV. Macular rod function in retinitis pigmentosa measured with scotopic microperimetry. Transl Vis Sci Technol. 2021; 10: 3. [CrossRef] [PubMed]
Kitagawa K, Nishida S, Ogura Y. In vivo quantitation of autofluorescence in human retinal pigment epithelium. Ophthalmologica. 1989; 199: 116–121. [CrossRef] [PubMed]
Delori FC. Spectrophotometer for noninvasive measurement of intrinsic fluorescence and reflectance of the ocular fundus. Applied Optics. 1994; 33: 7439–7452. [CrossRef] [PubMed]
von Rückmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol. 1995; 79: 407–412. [CrossRef] [PubMed]
von Ruckmann A, Fitzke FW, Bird AC. In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol. 1997; 115: 609–615. [CrossRef] [PubMed]
Paskowitz DM, LaVail MM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol. 2006; 90: 1060–1066. [CrossRef] [PubMed]
Cideciyan AV, Swider M, Jacobson SG. Autofluorescence imaging with near-infrared excitation: Normalization by reflectance to reduce signal from choroidal fluorophores. Invest Ophthalmol Vis Sci. 2015; 56: 3393–3406. [CrossRef] [PubMed]
Oh JK, Lima de Carvalho JR, Jr., Ryu J, Tsang SH, Sparrow JR. Short-wavelength and near-infrared autofluorescence in patients with deficiencies of the visual cycle and phototransduction. Sci Rep. 2020; 10: 8998. [CrossRef] [PubMed]
Lima de Carvalho JR, Jr., Paavo M, Chen L, Chiang J, Tsang SH, Sparrow JR. Multimodal imaging in Best vitelliform macular dystrophy. Invest Ophthalmol Vis Sci. 2019; 60: 2012–2022. [CrossRef] [PubMed]
Figure 1.
 
Visual function and serous detachment in Best vitelliform macular dystrophy. (A) Best corrected visual acuity as a function of age in patients with monoallelic BEST1 mutations. Connected symbols represent eyes with follow-up. (B) Horizontal OCT from the right eye of patient F1/P2 demonstrating 0 logMAR visual acuity in an eye with a large serous retinal detachment involving the fovea. Inset, NIR-RAFI image showing the location of the OCT in the eye with pseudo-hypopyon stage. (C) Foveal light-adapted cone sensitivity loss in eyes with foveal serous detachment. Eyes with better acuity have better sensitivity. (D) Rod and cone sensitivity losses in parafoveal areas with serous detachment. A, C, D Gray symbols or bars represent eyes with worse than 0.2 logMAR acuity.
Figure 1.
 
Visual function and serous detachment in Best vitelliform macular dystrophy. (A) Best corrected visual acuity as a function of age in patients with monoallelic BEST1 mutations. Connected symbols represent eyes with follow-up. (B) Horizontal OCT from the right eye of patient F1/P2 demonstrating 0 logMAR visual acuity in an eye with a large serous retinal detachment involving the fovea. Inset, NIR-RAFI image showing the location of the OCT in the eye with pseudo-hypopyon stage. (C) Foveal light-adapted cone sensitivity loss in eyes with foveal serous detachment. Eyes with better acuity have better sensitivity. (D) Rod and cone sensitivity losses in parafoveal areas with serous detachment. A, C, D Gray symbols or bars represent eyes with worse than 0.2 logMAR acuity.
Figure 2.
 
Ultra-wide field topography of outer retinal structure in BVMD. (A, B) Topographical maps of ONL thickness (gray map, center) and IS/OS to RPE distance (pseudocolor map, right) obtained from OCT scans (left) in a normal subject and in patient F3/P2. ONL is the major hyposcattering layer on the OCT, IS/OS and RPE peaks are highlighted with orange and brick red, respectively. Purple represents indeterminate regions. (C) Quantitation of the ONL thickness and IS/OS to RPE distance along the two cardinal meridians, horizontal and vertical, crossing the fovea. Black traces are data from individual BVMD eyes, green lines delimit the normal range. N, I, S, and T represent nasal, inferior, superior, and temporal retina, respectively.
Figure 2.
 
Ultra-wide field topography of outer retinal structure in BVMD. (A, B) Topographical maps of ONL thickness (gray map, center) and IS/OS to RPE distance (pseudocolor map, right) obtained from OCT scans (left) in a normal subject and in patient F3/P2. ONL is the major hyposcattering layer on the OCT, IS/OS and RPE peaks are highlighted with orange and brick red, respectively. Purple represents indeterminate regions. (C) Quantitation of the ONL thickness and IS/OS to RPE distance along the two cardinal meridians, horizontal and vertical, crossing the fovea. Black traces are data from individual BVMD eyes, green lines delimit the normal range. N, I, S, and T represent nasal, inferior, superior, and temporal retina, respectively.
Figure 3.
 
Detailed structure of the photoreceptor-RPE interface in BVMD. (A, C) OCT scan and the longitudinal reflectivity profile of a representative normal and two patients with BVMD in the superior and inferior retina locations. Schematic shows the 16 degrees eccentric location (black square) sampled. (B, D) Distances measured from the IS/OS peak to the cone OS tips (COST) representing COS length, to the rod OS tips (ROST) representing ROS length and to the RPE peak representing combination of outer segments, subretinal space, and the RPE thickness in the superior and inferior retina locations. Left panels show absolute thickness, and the right panels show the thickness difference from mean normal values. Gray rectangles delimit the 99th percentile (±2.33 SD) of the normal values for each parameter.
Figure 3.
 
Detailed structure of the photoreceptor-RPE interface in BVMD. (A, C) OCT scan and the longitudinal reflectivity profile of a representative normal and two patients with BVMD in the superior and inferior retina locations. Schematic shows the 16 degrees eccentric location (black square) sampled. (B, D) Distances measured from the IS/OS peak to the cone OS tips (COST) representing COS length, to the rod OS tips (ROST) representing ROS length and to the RPE peak representing combination of outer segments, subretinal space, and the RPE thickness in the superior and inferior retina locations. Left panels show absolute thickness, and the right panels show the thickness difference from mean normal values. Gray rectangles delimit the 99th percentile (±2.33 SD) of the normal values for each parameter.
Figure 4.
 
Relation of retinal ultrastructure and dark-adaptation kinetics. (A) Outer retinal ultrastructure at 10 degrees nasal to the fovea (schematic, black square) shows the thickness difference from mean normal for COS and ROS length and IS/OS to RPE distance similar to Figures 3B and 3D. Four patients had normal ONL thickness whereas one patient (F3/P2) had abnormally thinned ONL. (B) Dark-adaptation kinetics following a transient adapting light presented at time zero. Data from four patients (unfilled circles) are shown in comparison to normal data (filled gray circles). Symbols identify the individual patients plotted in panel A. (C) OCT scan of patient F3/P1-OS at the locus evaluated with dark-adaptation kinetics (white rectangle) demonstrating substantially diminished ONL thickness compared to a representative normal. (D) Dark-adaptation kinetics showing elevated thresholds before the adapting light, and exceedingly slow recovery timecourse after the adapting light.
Figure 4.
 
Relation of retinal ultrastructure and dark-adaptation kinetics. (A) Outer retinal ultrastructure at 10 degrees nasal to the fovea (schematic, black square) shows the thickness difference from mean normal for COS and ROS length and IS/OS to RPE distance similar to Figures 3B and 3D. Four patients had normal ONL thickness whereas one patient (F3/P2) had abnormally thinned ONL. (B) Dark-adaptation kinetics following a transient adapting light presented at time zero. Data from four patients (unfilled circles) are shown in comparison to normal data (filled gray circles). Symbols identify the individual patients plotted in panel A. (C) OCT scan of patient F3/P1-OS at the locus evaluated with dark-adaptation kinetics (white rectangle) demonstrating substantially diminished ONL thickness compared to a representative normal. (D) Dark-adaptation kinetics showing elevated thresholds before the adapting light, and exceedingly slow recovery timecourse after the adapting light.
Figure 5.
 
Long-term changes in retinal structure. (A) Long-term (17–21 years) follow-up of younger (20–23 years old at first visit) patients with BVMD. (B) Long-term (10–20 years) follow-up of older (34–47 years old at first visit) patients with BVMD. In each panel, OCT scans along the horizontal meridian crossing the fovea are shown at two ages. ONL thickness is quantified (gray trace first visit and black trace last visit) and compared to the normal range. Bar graphs show ONL thickness change (last minus first) sampled across the retina. Double arrows mark regions of thickening beyond the normal range and single arrows mark regions of thickening within the normal range.
Figure 5.
 
Long-term changes in retinal structure. (A) Long-term (17–21 years) follow-up of younger (20–23 years old at first visit) patients with BVMD. (B) Long-term (10–20 years) follow-up of older (34–47 years old at first visit) patients with BVMD. In each panel, OCT scans along the horizontal meridian crossing the fovea are shown at two ages. ONL thickness is quantified (gray trace first visit and black trace last visit) and compared to the normal range. Bar graphs show ONL thickness change (last minus first) sampled across the retina. Double arrows mark regions of thickening beyond the normal range and single arrows mark regions of thickening within the normal range.
Figure 6.
 
Late development of satellite lesions in both eyes of patient F1/P4. (A, D) NIR-RAFI results at ages 29, 37, and 43 years show development of de novo lesions (pink outlines) at age 43 years in Panel A and at ages 37 and 43 years in Panel D. (B, E) Representative OCTs demonstrate serous detachments in retinal locations (arrows in A and D) that were previously attached. (C, F) Ultrawide-field topography of the IS/OS to RPE distance shows arcuate regions of hyper-thickening in the superior paramacular retina at age 37 years preceding the development of de novo serous detachments 6 years later. Purple represents regions with indeterminate IS/OS to RPE distance.
Figure 6.
 
Late development of satellite lesions in both eyes of patient F1/P4. (A, D) NIR-RAFI results at ages 29, 37, and 43 years show development of de novo lesions (pink outlines) at age 43 years in Panel A and at ages 37 and 43 years in Panel D. (B, E) Representative OCTs demonstrate serous detachments in retinal locations (arrows in A and D) that were previously attached. (C, F) Ultrawide-field topography of the IS/OS to RPE distance shows arcuate regions of hyper-thickening in the superior paramacular retina at age 37 years preceding the development of de novo serous detachments 6 years later. Purple represents regions with indeterminate IS/OS to RPE distance.
Table.
 
Demographics and Genetics of Patients with BEST1-BVMD
Table.
 
Demographics and Genetics of Patients with BEST1-BVMD
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×